Clinical outcomes among patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who received treatment with a covalent BTK and BCL2 inhibitor in the United States: a real-world database study

A retrospective chart review looked at real-world options for patients with CLL who experienced disease progression during or after treatment with both BCL2 and BTK inhibitors. Overall real-world response rate to next line of therapy in these patients was 34.4%, with a median PFS of 9.2 months. Median overall survival from start of next line of therapy was 25.5 months. These data highlight the importance of continued development of effective, tolerable therapies to treat patients with CLL in this challenging clinical scenario.